Logotype for Shenzhen Mindray Bio-Medical Electronics Co Ltd

Mindray (300760) H2 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Shenzhen Mindray Bio-Medical Electronics Co Ltd

H2 2024 earnings summary

23 Jul, 2025

Executive summary

  • 2024FY revenue reached 36.7 billion RMB, up 5.1% year-over-year, with net profit attributable to shareholders at 11.7 billion RMB, up 0.7%.

  • Net operating cash flow for 2024FY was 12.4 billion RMB, a 12.4% increase year-over-year.

  • 2025Q1 saw revenue of 8.2 billion RMB, down 12.1% year-over-year, and net profit attributable to shareholders of 2.6 billion RMB, down 16.8%.

Financial highlights

  • Gross margin for 2024FY was 63.1%, down 1.07 percentage points year-over-year.

  • Net margin for 2024FY was 31.77%, down 1.38 percentage points year-over-year.

  • Total assets at 2024 year-end were 56.6 billion RMB, up 18.2% year-over-year; shareholders' equity rose 22.2% to 40.8 billion RMB.

  • Dividend payout ratio for 2024FY reached 65.1%, with total cash dividends of 7.6 billion RMB, up 8.1% year-over-year.

Outlook and guidance

  • Revenue in 2025 is expected to follow a typical pattern of a lower first half and higher second half, with a major turning point in year-over-year growth anticipated from Q3.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more